SDC1 and triple-negative breast carcinoma: In a preclinical study, the antibody-drug conjugate indatuximab ravtansine (BT062) showed complete remission, i.e., >95% reduction of median tumor volume in relation to controls, in triple-negative breast cancer xenografts with strong expression of CD138 in IHC [24].